Hydrocortisone sodium acetate

PreclinicalSmall molecule

Hydrocortisone sodium acetate is one of 5 small molecule programs targeting Congenital Adrenal Hyperplasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congenital Adrenal HyperplasiaActive, not recruiting

Congenital Adrenal HyperplasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Congenital Adrenal Hyperplasia

#DrugCompanyPhaseTrials

Crenessity

Neurocrine Biosciences

Phase 3

5 2

Lu AF95245

Lundbeck

Phase 2

1 3

Atumelnant

CCrinetics Pharmaceuticals Inc.

Phase 3

4 4

Actos

Takeda

Preclinical

1 5

Hydrocortisone sodium acetate

BBaylor College of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Congenital Adrenal Hyperplasia1 trial

Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia

Completed·—·N/A·NCT00529841·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hydrocortisone sodium acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydrocortisone sodium acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydrocortisone sodium acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baylor College of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBaylor College of Medicine

Hydrocortisone sodium acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Congenital Adrenal Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News